Active Substance: Brimonidine Tartrate.
Overview
Welcome to Dwaey, specifically on BRIMOCHEK 0.2% page.
This medicine contains an important and useful components, as it consists of
Brimonidine Tartrateis available in the market in concentration
Brimonidine Tartrate (0.2 %, 0.15%) Eye prep
General Brimonidine ophthalmic solution should be used with caution in patients with known hypersensitivity to other alpha-adrenoceptor agonists. Although brimonidine had minimal effect on blood pressure and heart rate of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Brimonidine has not been studied in patients with hepatic or renal impairment; caution should be exercised in treating such patients. Brimonidine should be used with caution in patients with depression, cerebral or coronary insufficiency. Lactation: It is not known whether this drug is excreted in milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Open-angle glaucoma, Ocular hypertension
This eye drops are contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication.This product is also contraindicated in patients receiving monoaminase oxidase inhibitor therapy.
Oral dryness,Conjunctival hyperemia,Allergic conjunctivitis,Eye pruritus,Rash,Photophobia,Headache,Fatigue,Dizziness,Dyspepsia,Blepharitis,Eye discharge
2
Brimonidine is an alpha 2-adrenoceptor agonist which works to reduce aqueous humor production and increase uveoscleral flow.
Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with beta-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.
Information not available